Gilead Sciences | GILD - Creditori Commerciali





Creditori Commerciali Cambiamento Data
AbbVie USD 3.59B 28.65B 2025-12
Agios Pharmaceuticals USD 13.75M 4.61M 2026-03
ALKERMES USD 102.36M 5.59M 2026-03
Alnylam Pharmaceuticals USD 126.63M 10.91M 2026-03
Amgen USD 19.52B 1.37B 2026-03
Biogen USD 358.5M 73.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 4.23B 659M 2026-03
Coherus Biosciences USD 9.91M 14.98M 2025-12
Eli Lilly USD 5.03B 350M 2026-03
Gilead Sciences USD 645M 70M 2026-03
GlaxoSmithKline GBP 14.34B 1.05B 2026-03
Glaxosmithkline GBP 20.72B 346.14M 2025-12
Incyte USD 228.62M 1.41B 2026-03
J&J USD 10.46B 1.53B 2026-03
Merck USD 3.86B 541M 2026-03
Moderna USD 161M 156M 2026-03
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Novartis USD 4.32B 134M 2026-03
Pfizer USD 4.51B 734M 2026-03
PTC Therapeutics USD 25.48M 20M 2026-03
Puma Biotechnology USD 6.39M 962K 2025-09
Regeneron Pharmaceuticals USD 1.03B 4.81B 2026-03
Sangamo BioSciences USD 10.74M 7.46M 2025-06
Sanofi EUR 22.71B 219M 2026-03
Sarepta Therapeutics USD 70.38M 210.46M 2026-03
United Therapeutics USD 498.3M 491.2M 2026-03
Vertex Pharmaceuticals USD 3.47B 40.6M 2026-03